

## Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival

Steven M. Kornblau,<sup>1\*</sup> Peter P. Ruvolo,<sup>1\*</sup> Rui-Yu Wang,<sup>1</sup> V. Lokesh Battula,<sup>1</sup> Elizabeth J. Shpall,<sup>2</sup> Vivian R. Ruvolo,<sup>1</sup> Teresa McQueen,<sup>1</sup> YiHua Qui,<sup>1</sup> Zhihong Zeng,<sup>1</sup> Sherry Pierce,<sup>1</sup> Rodrigo Jacamo,<sup>1</sup> Suk-Young Yoo,<sup>3</sup> Phuong M. Le,<sup>1</sup> Jeffrey Sun,<sup>1</sup> Numsen Hail Jr,<sup>1</sup> Marina Konopleva<sup>1</sup> and Michael Andreeff<sup>1</sup>

<sup>1</sup>Section of Molecular Hematology and Therapy, Department of Leukemia; <sup>2</sup>Department of Stem Cell Transplantation and <sup>3</sup>Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, TX, USA

*\*SMK and PPR contributed equally to this work.*

©2018 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2017.172429

Received: May 9, 2017.

Accepted: February 1, 2018.

Pre-published: March 15, 2018.

Correspondence: skornblau@mdanderson.org or mandreeff@mdanderson.org

---

1 **Kornblau et al Supplemental Materials**

2

3 **Supplemental Methods**

4 **Isolation and culture of primary MSC from bone marrow**

5 MSC were isolated from bone marrow (BM) of consented AML patients undergoing diagnostic  
6 BM aspiration and from healthy donors who were undergoing BM harvest for use in allogeneic  
7 BM transplantation. BM was subjected to centrifugation (700 g for 15 minutes at 4°C) over a  
8 Ficoll-Hypaque (Sigma-Aldrich) gradient to separate mononuclear cells. After centrifugation, the  
9 buffy coat layer was carefully extracted and suspended in  $\alpha$ MEM (Cellgro, Mediatech, Inc.)  
10 supplemented with 10% pooled human platelet lysate (pHPL, kindly provided by Dr. Dirk  
11 Strunk, Department of Hematology and Stem Cell Transplantation, Medical University of Graz,  
12 Austria), 1 supplemented with 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL  
13 streptomycin (Sigma-Aldrich). The BM mononuclear cell content was analyzed by automated  
14 blood count (Beckman Coulter), and mononuclear cells were seeded at a density of  $5 \times 10^4$   
15 cells/cm<sup>2</sup> in tissue-culture flasks and cultured at 37°C in 5% CO<sub>2</sub> incubator. The non-adherent  
16 cells were removed by completely changing the medium after 3 days, and the adherent cells were  
17 continuously cultured. The cultures were fed twice weekly by replacing 30% of the medium with  
18 fresh supplemented medium. The cells were harvested before reaching confluence by applying  
19 0.25% trypsin and 1 mM EDTA (Life Technologies). MSC were cryopreserved and early  
20 passage (passage 2-3) samples were used for study. As observed in our previous studies, isolated  
21 MSC are CD73+/CD90+/CD105+ (see references 4 and 14 in the manuscript).

22 **Flow Cytometry**

23 Flow cytometry to assess standard MSC lineage markers on MSC were performed using  
24 antibodies against CD73-PE (PE; BD), CD105-PE (PE; eBioscience) and CD90 (APC-Cy7;

25 Beckman Coulter). Cells were analyzed on LSR-II flow cytometer and the data was analyzed  
26 using FlowJo software.

27

### 28 **Immunoblot analysis**

29 Cells were lysed and protein transferred to a membrane and western blotting analysis performed  
30 with antibodies against p53, p21 (both from Santa Cruz Biotechnology, Dallas, TX) and Tubulin  
31 (Sigma-Aldrich). Signals were detected by using the Odyssey Infrared Imaging System and  
32 quantitated by Odyssey software version 3.0 (both LI-COR Biosciences, Lincoln, NE). Tubulin  
33 was used as a loading control.

34

### 35 **Gene and miR expression analysis**

36 Real-time PCR (qRT-PCR) was conducted using an ABI 7900HT Fast Real-Time PCR System  
37 (Life Technologies). We ran duplicate 20 µl reactions containing the equivalent of 1 ng total  
38 RNA). We used the following TaqMan Gene Expression Assays (Life Technologies) as directed  
39 by the manufacturer: p53 (TP53; Hs01034249\_m1), BCL-X<sub>L</sub> (BCL2L1; Hs00236329\_m1),  
40 TP53INP1 (Hs01003820\_m1), BBC3 (Hs00248075\_m1), CDKN1A (Hs00355782\_m1),  
41 CCND1 (Hs00765553\_m1), and 18S (Hs03928985\_g1). For miR analysis, Taqman assays for  
42 miR-93 (000432) and U6 snRNA (#001973) were used. We used RQ Manager 1.2.1 (Life  
43 Technologies) to analyze the data.

44


### 45 **Statistical analyses**

46 For RPPA, supercurve algorithms were used to generate a single value from the five serial  
47 dilutions.<sup>28-31</sup> Loading control and topographical normalization procedures accounted for protein



48 concentration and background staining variations.<sup>28-31</sup> Analysis using unbiased hierarchical  
49 clustering perturbation bootstrap clustering, and principle component analysis was then done as  
50 fully described in a previous publication using available R packages and Qlucore software  
51 (Version 3.1, Qlucore Inc. Lund Sweden).<sup>28-31</sup> Comparison of the protein levels between paired  
52 samples was done by performing paired *t* test. Association between protein expression levels and  
53 categorical clinical variables were assessed in R using standard *t* tests, linear regression, or  
54 mixed effects linear models. Unbiased hierarchical clustering was performed using the weighted  
55 average method and the associated figures show expression normalized to median = 0, variance  
56 = 1. The *P*-value and the associated Q-value (a measure of the false discovery rate) are shown  
57 for each clustering analysis. Association between continuous variable and protein levels were  
58 assessed by using the Pearson and Spearman correlation and linear regression. Bonferroni  
59 corrections were done to account for multiple statistical parameters for calculating statistical  
60 significance.

61

62 **Supplemental Figures**  
63



64  
65 Supplemental Figure 1. AML MSC and NL MSC express MSC lineage markers. Flow cytometry  
66 on three representative Normal MSC and three representative AML MSC was performed using  
67 CD73, CD90, and CD105 antibodies. Data was analyzed by FlowJo.  
68

**A****B**

69

70 Supplemental Figure 2. Protein expression is distinct between MSC and blood cells. PCA (A)  
71 and heat map (B) of hierarchical clustering of 151 proteins examined in AML MSC (blue), NL  
72 MSC (light blue), AML blasts (pink) and normal CD34+ cells (green) is depicted.


73

74

75

76

77



79

80

81


82 Supplemental Figure 3. Validation of expression of proteins that are elevated in AML MSC as  
 83 identified by RPPA. Protein was isolated from AML derived MSC (n = 3). Immunoblot analysis  
 84 performed with antibodies against STAT1, PDK1, CK2, CCND1, GSK3 A/B, SPP1, CDK4,  
 85 p53, BCL-X<sub>L</sub>, ITGA2, NOTCH 1, PPP2R2A, STAT5A/B, DIABLO, p21, PARP1, and BAK1.  
 86 Tubulin was included as control for each filter analyzed. Images were obtained using LiCor  
 87 imager.

88

89


90

**A**



Age	Under 30	30-49	50-59
AML MSC (N)	13	17	20
NL MSC (N)	37	25	6



**B**




91 Supplemental Figure 4. Expression of various proteins are different in normal versus AML MSC  
 92 across different age groups. (A) Protein expression as determined by RPPA for BCL-X<sub>L</sub> and  
 93 PPP2R2A/B/C/D are compared among AML patients and healthy individuals in age groups of  
 94 under 30 years old (left), 30-49 years old (center) and 50-59 years old (right). Statistical analysis  
 95 was performed as described in “Methods”. (B) Protein was isolated from normal donor MSC (n  
 96 = 3) and AML derived MSC (n = 3) from individuals 40-49 years old. Immunoblot analysis  
 97 performed with antibodies against phosphorylated ERK, MCL-1, p53, and Tubulin. Ratio of  
 98 protein expression to Tubulin loading control was determined by densitometry using LiCor  
 99 imager.

100  
 101  
 102






103  
 104 Supplemental Figure 5. STAT5 expression is differentially correlated with STAT1 and hnRPK in  
 105 normal and AML MSC. Pearson correlation of protein expression as determined by RPPA with  
 106 STAT5 demonstrates differences between normal (A) and AML (B) MSC. Reverse correlations  
 107 are found with STAT1 (green) and hnRPK (black).  
 108




109  
 110 Supplemental Figure 6. Ingenuity Pathway Analysis Reveals Proteins Identified by Unbiased  
 111 Clustering in Group 3 Proteins (Elevated in Normal MSC) Are Involved in Adipogenesis.  
 112 Signature Proteins Are Denoted In Pink.


113  
 114  
 115  
 116  
 117



118  
 119 Supplemental Figure 7. Ingenuity Pathway Analysis Reveals Proteins Identified by Unbiased  
 120 Clustering in Group 1 and Group 2 (Elevated in AML MSC) Are Involved in In PI3K/AKT  
 121 Signaling (Right). Signature Proteins Are Denoted In Pink.  
 122



123  
 124 Supplemental Figure 8. Ingenuity Pathway Analysis (Software from Qiagen) Reveals Proteins  
 125 Identified by Unbiased Clustering in salvage versus newly diagnosed MSC from AML patients  
 126 Are Involved In osteoblast differentiation. Signature Proteins Are Denoted In Pink.  
 127



128  
 129 Supplemental Figure 9. Gene expression in AML and normal MSC. RNA was isolated from  
 130 AML MSC (n = 10) and normal MSC (n = 9) and qRT-PCR performed to measure expression of  
 131 BCL2L1, CCND1; PPP2R2A, and CDKN1A. Expression was normalized to 18S.  
 132

133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143

144 Supplemental Table 1: List of proteins analyzed by RPPA.

AKT	FOXO1p24.FOXO3p32	PA2G4.pT37.p46
AKT1	FOXO3	PA2G4.pT70
AKT1.2.3.p308	FOXO3.p318.321	PARK7
AKT1.2.3.p473	GAB2	PARP1
AKT1S1	GAB2.p452	PDK1
AKT1S1.p	GAPDH	PDK1.p241
AKT2	GATA3	PECAM1
AKT3	GSKA.B	PPARG
ARC	GSKA.B.p21.9	PPP2R2A/B/C/D
ATF3	HDAC3	PRKAA1.2
BAD	HIF1A	PRKAA1.2.p172
BAD.p112	HNRNPK	PSMD9
BAD.p136	HSP90AA1.B1	PSMD9.1
BAD.p155	HSPA1A.L	PTEN
BAK1	HSPB1	PTGS2
BAX	INPP5D	PTK2
BCL2	IRS1.phospho.ser.1101	RAC1.2.3
BCL2L1	ITGA2	RELA
BCL2L11	ITGAL	RPS6
BECN1	ITGB3	RPS6.p235.236
BID	JMJD6	RPS6.p240.244
BIRC5	JUN.p73	RPS6KB1
CAV1	JUNB	RPS6KB1.ph389
CCNB1	KDR	SFN
CCND1	KIT	SIRT1
CCND3	LCK	SMAD1
CCNE1	LEF1	SMAD4
CD34	LGALS3	SMAD6
CDK1	LYN	SPP1
CDK2	MAP2K1	SQSTM0
CDK4	MAP2K1.2.p217.221	SRC
CDKN1A	MAPK1	SRC.p416
CREB1	MAPK1.3.p202.204	SRC.p527
CREB1.p133	MAPK14	STAT1
CSNK2A1	MAPK14.1	STAT1.p701
CTNNA1	MAPK8	STAT3
CTNNB1	MAPK9	STAT3.p705
CTNNB1.p33.37.41	MCL1	STAT3.p727
DIABLO	MDM2	STAT5A.B
EGFR	MS4A1	STAT5A.B.p694
EGFR.p992	MSI2	STK11

EGLN1	MTOR	STMN1
EIF2S1	MTOR.p2448	TCF4
EIF2S1.p51.	MYC	TGM2
EIF4E	NOTCH1.cl1744	TP53
ELK1.p383	NOTCH3	TP53.1
ERBB2	NPM1.1	TSC2
ERBB2.p1248	NR4A1	VHL
ERG	NRP1	XIAP
FN1	PA2G4	YWHAE
		YWHAZ

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163 Supplemental Table 2: Expression of proteins as determined by RPPA in AML MSC and normal  
 164 MSC according to age. Statistically significant ( $p < 0.05$ ) values are in **bold**. An \* follows values  
 165 with  $p > 0.05$ .

166 Elevated AML-MSc

Proteins n =18	p value Age < 30 n =13	p value Age 31-49 n =17	p value Age 50-59 n =20
Statistically significant in all groups n =2			
BCL2L1 (BCL-X <sub>L</sub> )	<b>0.015</b>	<b>0.005</b>	<b>0.033</b>
PPP2R2A/B/C/D	<b>0.006</b>	<b>0.002</b>	<b>0.015</b>
Statistically significant in two groups (n = 8)			
CSN2KA1	<b>0.020</b>	0.063*	<b>0.002</b>
STAT5A/B	<b>0.002</b>	<b>0.022</b>	0.068*
TP53	<b>0.005</b>	0.288*	<b>0.001</b>
CDKN1A (p21)	<b>0.011</b>	<b>0.011</b>	0.715*
CDK4	<b>0.001</b>	<b>0.042</b>	0.715*
ERBB2	<b>0.025</b>	<b>0.013</b>	0.503*
GSK3A/B	<b>0.048</b>	0.121*	<b>0.015</b>
STAT1	<b>0.025</b>	<b>0.001</b>	0.670*
Statistically significant in one group (n = 6)			
p-PDK1 (S241)	<b>0.007</b>	0.079*	0.361*
ITGA2	0.154*	<b>0.002</b>	0.224*
PARP1	0.799*	<b>0.010</b>	0.162*
CCND1	0.160*	<b>0.001</b>	0.855*
BAK1	0.109*	0.084*	<b>0.029</b>
SPP1	0.800	<b>0.017</b>	0.334
Statistically significant in no groups (n = 2)			
NOTCH (cleaved 1744)	0.228*	0.079*	0.761*
DIABLO	0.109*	0.196*	0.144*

167 Elevated NL MSC

Proteins n =7	p value Age < 30 n =37	p value Age 31-49 n =25	p value Age 50-59 n =6
------------------	---------------------------	----------------------------	---------------------------



Statistically significant in all groups n = 0			
Statistically significant in two groups (n = 2)			
SMAD4	<b>0.028</b>	<b>0.014</b>	0.144*
STMN1	<b>0.021</b>	<b>0.001</b>	0.543*
Statistically significant in one group (n = 4)			
EIF2S1	<b>0.041</b>	<b>0.010</b>	0.162*
SMAD1	0.370*	<b>0.003</b>	0.626*
SIRT1	0.099*	<b>0.013</b>	0.543*
p-Foxo1/3 (S32)	0.167*	<b>0.001</b>	0.465*
Statistically significant in no groups (n = 1)			
HSP90AA1/B1	0.083*	0.247*	0.503*

168

169

170